Alembic Pharmaceuticals Limited (APLLTD)
Please find attached Investor Presentation.
Investor Presentation - Q1 FY27
- Revenue 21.50bn +26% y-y; EBITDA margin before R&D ~24%; PAT margin 8%
- India Branded Business revenue grew 7% y-y to 6.42bn; ranked 21st in Indian pharma market
- US Formulation revenue up 49% y-y driven by new product launches; 7 products launched in Q1
- Ex-US Formulation revenue increased 17% y-y with expansion in global markets
- API business grew 33% y-y supported by strong order book and 3 US DMF filings
- R&D spend at 9% of revenue focusing on peptide development and increased filings
- EBITDA after R&D margin at 16% with operating leverage expansion
- Sustainability targets include net zero by 2050 and water neutrality by 2027
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 APLLTD — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add APLLTD to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alembic Pharmaceuticals Limited
Important.
The summary above is generated automatically from Alembic Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.